Mitochondrial permeability transition pore-targeting composition for treating hearing loss

A compound targeting the mitochondrial permeability transition pore inhibits its activity, addressing cisplatin-induced ototoxic hearing loss by reducing ROS levels and maintaining mitochondrial integrity, effectively preventing cellular damage and apoptosis.

WO2025259057A9 Publication Date: 2026-02-12KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND +1
0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2025/008165
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-06-14
Filing Date
2025-06-13
Publication Date
2026-02-12

AI Technical Summary

Technical Problem

Current treatments have not effectively addressed the role of mitochondrial permeability transition pore (mPTP) in hearing loss, particularly ototoxic hearing loss induced by cisplatin, leading to cellular damage and apoptosis.

Method used

A compound targeting the mitochondrial permeability transition pore (mPTP) is developed, inhibiting its activity and opening, thereby reducing intracellular ROS levels, maintaining mitochondrial membrane potential, and preventing apoptosis in auditory cells.

Benefits of technology

The compound effectively prevents cisplatin-induced ototoxic hearing loss by inhibiting mPTP opening, preserving mitochondrial function and reducing cellular damage, thus protecting inner and outer hair cells.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to a mitochondrial permeability transition pore (mPTP)-targeting composition for treating hearing loss, and, more specifically, uses a compound, or a pharmaceutically / sitologically acceptable salt thereof, which targets the mitochondrial permeability transition pore (mPTP) to inhibit the activity or opening thereof, and thus can effectively prevent, alleviate, or treat hearing loss caused by mPTP opening.
Need to check novelty before this filing date? Find Prior Art